Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 2, 2006, Pages 161-165

  Popnikolov, Nikolay K ^a,d   Gatalica, Zoran ^b   Adegboyega, Patrick A ^c   Norris, Brent A ^c   Pasricha, P Jay ^c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d GRADUATE HOSPITAL   (United States)

Author keywords

Barrett's esophagus; Dysplasia; Esophageal adenocarcinoma; TRAIL Apo2L

Indexed keywords

FAS ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; COLON MUCOSA; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SMALL INTESTINE; STOMACH;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINES; STOMACH; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 33745426578     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000157905.30872.9f     Document Type: Article

References (29)

1. Vizcaino AP, Moreno V, Lambert R, et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002;99:860-868.
2. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer. 2003;3:676-684.
3. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by APO-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687-12690.
4. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682.
5. Mariani SM, Matiba B, Armandola EA, et al. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol. 1997;137:221-229.
6. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science. 1997;276:111-113.
7. Pan G, Ni J, Wei Y-F, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997;227:815-818.
8. Sheridan JP, Marsters SA, Pitti PM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818-821.
9. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997;16:5386-5397.
10. Degli-Esposti MA, Smolak PJ, Walczac H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med. 1997;186:1165-1170.
11. Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF-kB and protects against TRAIL-mediated apoptosis, yet retains and incomplete death domain. Immunity. 1997;7:813-820.
12. Marsters SA, Sheridan JP, Pitti PM, et al. A novel receptor for Apo2/TRAIL contains truncated death domain. Curr Biol. 1997;7:1003-1006.
13. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998;10:559-563.
14. Popnikolov N, Norris BA, Pasricha PJ, et al. TRAIL/APO2L expression during colonic carcinogenesis and its correlations with CD95/FAS and p53. Mod Pathol. 2001;14:93A.
15. Strater J, Hinz U, Walczak H, et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res. 2002;8:3734-3740.
16. Strater J, Walczak H, Pukrop T, et al. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. Gastroenterology. 2002;122:659-666.
17. Gong B, Almasam A. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemia cells. Cancer Res. 2002;60:5754-5760.
18. Zhou Q, Fukushima P, DeGraff W, et al. Radiation and Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast epithelial cells overexpressing cyclin D1. Cancer Res. 2000;60:2611-2615.
19. Walczak H, Krammer PH. TheCD95(APO-TheCD1/FAS) and TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 2000;256:58-66.
20. Gong B, Almasam A. Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. Biochem Biophys Res Commun. 2000;278:747-752.
21. Inoue H, Shiraki K, Yamanaka T, et al. Functional expression of tumor necrosis factor-related apoptosis-inducing ligand in human colonie adenocarcinoma cells. Lab Invest. 2002;82:1111-1119.
22. Orlovski K, Teodor L, Malovani K, et al. Gamma interferon (IFN-gamma) down-regulates Fer and induces its association with inactive STAT3 in colon carcinoma cells. Oncogene. 2002;21:4997-5001.
23. Pfizenmaier K, Bartch H, Scheurich P, et al. Differential gamma-interferon response of human colon carcinoma cells: inhibition of proliferation and modulation of immunogenicity as independent effect of gamma-interferon on tumor cell growth. Cancer Res. 1985;45:3503-3509.
24. Susuki S, Mita S, Kamohara H, et al. IL-6 and INF-gamma regulation of IL-10 production by human colon carcinoma cells. Int J Oncol. 2001;18:581-586.
25. Wang Q, Ji Y, Wang X, et al. Isolation and molecular characterization of the 5′-upsteam region of the human TRAIL gene. Biochem Biophys Res Commun. 2000;276:466-471.
26. Kumar-Sinha C, Varambally S, Sreekumar A, et al. Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem. 2002;277:575-585.
27. Bromberg JF, Horvath CM, Wen Z, et al. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA. 1996;93:7673-7678.
28. Mitelman Database of Chromosome Aberration in Cancer [database online]. Bethesda, MD: National Cancer Institute; 2004.
29. Rao PH, Mathwe S, Kelsen DP, et al. Cytogenetics of gastric and esophaseal adenocarcinomas. Cancer Genet Cytogenet. 1995;81:139-143.